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Background: Neoplastic and bland portal vein thrombi (PVT) are both common in patients with hepatocellular
carcinoma (HCC). The correct discrimination of them is essential for therapeutic strategies planning and survival
predicting. The current study aims to investigate the value of susceptibility-weighted imaging (SWI) in differentiating
bland from neoplastic PVT in HCC patients.
Methods: 20 HCC patients with bland PVT and 22 HCC patients with neoplastic PVT were imaged with non-contrast
SWI at 3.0 Tesla MRI. The signal intensity (SI) of the PVT and HCC lesions in the same patients was compared on SW
images. The phase values of the PVT were compared between neoplastic and bland thrombi cohorts. Receiver operator
characteristics (ROC) analysis was conducted to evaluate the diagnostic ability of the phase values for neoplastic and
bland thrombi discrimination.
Results: 20 of 22 neoplastic PVT were judged similar SI and 2 were judged lower SI than their HCC. For 20 bland PVT,
19 were judged lower SI and 1 was judged similar SI as their HCC (P<0.001). The average phase values (0.361 ± 0.224)
of the bland PVT were significantly higher than those of the neoplastic PVT (−0.328 ± 0.127, P<0.001). The AUC for
phase values in differentiating bland from neoplastic PVT was 0.989. The best cut-off value was −0.195, which gave a
sensitivity of 95% and a specificity of 95.5%.
Conclusions: SW imaging appears to be a promising new method for distinguishing neoplastic from bland PVT. The
high sensitivity and specificity suggest its high value in clinical practice.
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Portal vein thrombosis is a form of venous thrombosis
affecting the hepatic portal vein, which can lead to portal
hypertension and a reduction in the blood supply to
the liver. Neoplastic portal vein thrombus is found in
6.5%–44% of patients with hepatocellular carcinoma
(HCC). It renders a patient unsuitable for aggressive
treatment approaches, such as surgical resection or
chemoembolization, due to the unusually high incidence
of tumor recurrence [1-3]. Bland thrombus occurs in* Correspondence: willyxt@163.com; wangjian_1964@sohu.com
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unless otherwise stated.4.5%–26% of patients with chronic liver disease and in
42% of patients with HCC. It can be resolved after
thrombolytic and anticoagulant therapy [4,5]. Neoplastic
and bland portal vein thrombi discrimination is of great
clinical significance for determining the therapeutic ap-
proach, predicting survival, and assessing candidates for
liver transplantation.
T2*-weighted imaging (T2*WI) is sensitive to ferri-
hemoglobin and hemosiderin based on the local field
inhomogeneity generated by the paramagnetic effect of
iron particles. T2*WI has been proven useful in cere-
bral venous thrombosis detection and evaluation [6].
Susceptibility-weighted imaging (SWI), which exploits
the susceptibility differences between tissues as a newhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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field inhomogeneity by adding phase information to
the T2* contrast. SWI phase imaging avoids the impact
of main magnetic field inhomogeneity through the imple-
mentation of a high-pass filter [7]. Three-dimensional (3D)
SWI has been proven superior to T2* and other existing
magnetic resonance imaging (MRI) techniques for the de-
tection of iron content and hemorrhage in brain [8,9].
Two-dimensional SWI is a newer approach than 3D SWI,
and it is nearly immune to breathing artifacts because it
takes advantage of breath-holds. This technique has been
successfully applied to the analysis of cirrhotic livers [10].
The value of SW imaging has not, to our knowledge, been
studied for characterizing intravascular thrombosis in the
liver. The purpose of this study was to investigate the value
of SW imaging in distinguishing a bland thrombus from
a neoplastic thrombus of the portal vein in patients with
HCC.Methods
Subjects
This HIPAA-compliant study was approved by the ethics
commission of Southwest Hospital of China and written
informed consent was obtained from each patient. From
Oct 2011 to Dec 2013, 46 consecutive patients who had
pathology-confirmed HCC and portal vein thrombus
(PVT) participated in this study. 4 patients were excluded
because of the following: a history of hepatic surgery,
coexisting bland and neoplastic thrombi, or an unsuccess-
ful examination resulting from body movement and arti-
facts. Thus, a total of 42 patients (20 men and 22 women,
with a mean age of 45.3 years, range of 36–65 years; a
mean weight of 71.56 kg, range of 47–98 kg) including 22
neoplastic PVT and 20 bland PVT formed the final study
cohort. The PVT was localized in: the main portal trunk
in 12 cases, the right branch in 16 cases, the left branch in
10 cases, and a combination of these in 4 cases. PVT of 22
patients were confirmed by surgery, 10 were confirmed by
biopsy, and 10 were diagnosed based on other imaging
criteria according to the litarature [11-14].Computed tomographic imaging
Contrast-enhanced multiphase CT was performed with
a multi-detector dual-source CT (Definition, Siemens
Healthcare, Forchheim, Germany). The examination con-
sisted of precontrast images and three dynamic phase
images acquired 35 s (hepatic arterial phase), 70 s (por-
tal venous phase), and 180 s (delayed phase) following
the intravenous administration of 100–120 ml Ultravist
370 (Bayer-Schering, Leverkusen, Germany) at a rate
of 3–4 ml/s. The imaging parameters were as follows:
250 mAs, 120 kVp, and 1.2 mm beam collimation with
a 0.5 s gantry rotation time. The field of view (FOV)was 35 cm, with a reconstruction thickness and interval of
5 mm.
Magnetic resonance imaging
MR imaging was performed with a 3.0 T whole body
system (Magnetom Trio, Siemens Healthcare, Erlangen,
Germany) using a standard 12-channel matrix coil with-
out intravenous contrast enhancement. The following MR
pulse sequences were used: transverse T1-weighted 2D
gradient echo (GRE) (flip angle 70°, TR/TE 140/2.46 ms),
transverse T2-weighted 2D fast spin echo (flip angle 122°,
TR/ TE =3700/84 ms) and transverse abdominal 2D SWI
(flip angle 20°, TR/TE = 150/10 ms). For all of the patients,
the following parameters were used: FOV 280 × 285 mm2;
matrix 384 × 250; 30 slices; and a slice thickness of 5 mm
with a gap of 1 mm. The protocol for SWI was similar to
that used in a previous study [10]. Three breath-holds
were used, each lasting 16 seconds. The total acquisition
time was not longer than 1 minute and 20 seconds, in-
cluding the break time between the breath holds. SWI
postprocessing was done inline and consisted of the
following steps: 1) Original images from each channel
were passed through a 32 × 32 high pass filter to re-
move background artifacts; 2) The highpass filtered
images from each channel were weighted by the coil
sensitivity factor and combined to generate a single
complex image; 3) highpass filter corrected phase images
were created from the final complex images; 4) a normal-
ized phase mask was calculated from each corrected
phased image and multiplied with the magnitude image to
produce the final SWI and phase image [7].
Image analysis
All of the SWI images were evaluated with SPIN software
(Signal Processing in NMR, Version 1751, MRI Institute for
Biomedical Research, Detroit, MI, USA; http://www.mrima-
ging.com/category.88.html) by two reviewers who were
unaware of the bland or neoplastic nature of the thrombi
and who had no access to the other sequences. All SW
Images were evaluated qualitatively and then quantitatively.
Qualitative analysis
For qualitative analysis, the readers were asked to compare
the signal intensity (SI) of the portal vein thrombi with
those of the HCC on the SW images. They classified the
SI of the portal vein thrombi into the following categories:
higher, equal to, or lower than the SI of the HCC. The
readings were performed separately.
Quantitative analysis
Regions of interest (ROI) were drawn directly to delineate
the entire HCC and PVT, avoiding any vessels and hemor-
rhages (Figure 1). The mean and standard deviation (SD)
of the Siemens Phase Unit (SPU) were obtained from the
Figure 1 Example of the ROI over the tumor and thrombus. Red lines delineate the HCC and PVT, green lines delineate a hemorrhages in
the HCC.
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equation: (SPU-2048) x π /2048 [15]. The phase values of
the tumors in the neoplastic and bland cohorts were com-
pared using the Mann–Whitney test. The phase values of
the tumors and thrombi were compared in each group
using the Wilcoxon matched pairs signed rank test. The
phase values of the thrombi of the two cohorts were com-
pared using the Mann–Whitney test. P values <0.05 were
considered statistically significant. Receiver operator char-
acteristics (ROC) analysis was conducted to evaluate the
diagnostic ability of phase values for neoplastic and bland
thrombi discrimination. The areas under the ROC curve
(AUC) and the confidence intervals (CIs) were assessed.
The cut-off values that maximized the sum of the sensitiv-
ity and specificity were determined and set as the point in
the most upper left hand corner. All statistical analyses
were performed with the SPSS 17.0 software package
(SPSS Inc., Chicago, IL, USA).
Results
Qualitative analysis
20 of 22 neoplastic thrombi were judged similar SI and 2
were judged lower SI than their HCC. For 20 bland
thrombi, 19 were judged lower SI and 1 were judged similar
SI as their HCC (P<0.001) (Figures 2 and 3). There is no
significant difference between the two readers (P>0.05).
Quantitative analysis
There is a significant phase value difference between
bland thrombi (0.361 ± 0.224) and neoplastic thrombi
(−0.328 ± 0.127, P<0.001). The AUC for phase values in
differentiating bland from neoplastic PVT was 0.989. The
best cut-off value was −0.195, which gave a sensitivity of
95% and a specificity of 95.5% (Figures 4 and 5).
No statistically significant difference was found between
the phase values of the HCC in the neoplastic and bland
cohorts (−0.340 ± 0.067, and −0.326 ± 0.049 respectively;
P>0.05). No statistically significant difference was found
between the phase values of the thrombi (−0.328 ± 0.127)and the HCC (−0.340 ± 0.067) in the neoplastic PVT group
(P>0.05). The phase values of the thrombi (0.361 ± 0.224)
were significantly higher than those of the corresponding
HCC (−0.326 ± 0.049) in the bland PVT group (P<0.001).
Discussion
The importance of neoplastic and bland portal vein
thrombosis discrimination in patients with HCC is well
recognized. Bland thrombus develops from sluggish portal
blood flow and can be resolved after thrombolytic and
anticoagulant therapy. Neoplastic portal vein thrombus is
often caused by the direct invasion of HCC and renders a
patient unsuitable for aggressive treatment approaches,
such as surgical resection, orthotopic liver transplantation,
or chemoembolization, due to the unusually high inci-
dence of tumor recurrence. Neoplastic PVT has also been
shown to be an important factor in determining the prog-
nosis of patients with HCC. The five-year survival after
surgical resection is 12%–39% in patients with neoplastic
vascular invasion and 59% in those without [16-18].
Magnetic resonance imaging is of great value in the
assessment of PVT [19]. To our knowledge, this is the
first study of PVT analysis by SWI. We found that most
SWI SI of neoplastic portal vein thrombi were similar to
those of the coexisting HCC, whereas the SI of the bland
thrombi were generally lower than those of the coexisting
HCC. The phase value difference between neoplastic and
bland PVT were statistically significant. The best cut-off
value of −0.195 (in radians) gave a sensitivity of 95% and a
specificity of 95.5%. These results suggest that SWI is a
promising tool that can be used for the diagnosis of neo-
plastic and bland PVT. Quantitative phase shift analysis is
better than qualitative SI analysis. Neoplastic and bland
thrombi are formed through different pathophysiological
mechanisms. Bland thrombus develops from sluggish por-
tal blood flow and is characterized by the presence of
fibrin or blood clots without viable cells. SW imaging is an
MR technology that has been shown to be sensitive to
ferrihemoglobin and hemosiderin, which have only
Figure 3 Neoplastic thrombosis of the portal vein in a patient with hepatocellular carcinoma (HCC). A: Contrast-enhanced multidetector
computer tomography (CE-CT); B: T1-weighted imaging (T1WI); C: T2-weighted imaging (T2WI); and D: Susceptibility-weighted imaging (SWI). A
large HCC (*) is seen in the right lobe of the liver and invades the right portal vein (white arrow). The HCC and portal vein thrombus display
similar signal intensity (SI) by SW imaging.
Figure 2 Bland thrombosis of the portal vein in a patient with hepatocellular carcinoma (HCC). A: Contrast-enhanced multidetector computer
tomography (CE-CT); B: T1-weighted imaging (T1WI); C: T2-weighted imaging (T2WI); and D: Susceptibility-weighted imaging (SWI). HCC (*) is seen
occupying the right lobe of the liver. A filling defect is noted in the right portal vein (white arrow), which exhibits lower signal intensity (SI) than the
tumor by SWI.
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Figure 4 Phase values (in radians) of neoplastic and bland portal vein thrombi (PVT).
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not require intravenous contrast agents or exposure to
radiation. This property makes SWI suitable for repeated
examinations and follow-up studies, especially for preg-
nant patients or for patients with a contradiction to con-
trast media administration.
The reference standard for characterizing portal vein
thrombosis is histopathologic examination. However, portalFigure 5 Receiver operating characteristics curves for phase values
(PVT) discrimination.vein thrombus biopsy is an invasive procedure with an
associated risk of bleeding [20-23]. Contrast-enhanced
ultrasound is notorious for being user dependent, can
be difficult in obese patients and is sometimes hampered
by the presence of bowel gas [24,25]. CE-CT is generally
accepted as a reliable tool in identifying and characterizing
portal vein thrombosis. The imaging criteria for malignant
and benign thrombi discrimination using CT are well(in radians) in neoplastic and bland portal vein thrombi
Li et al. BMC Cancer 2014, 14:590 Page 6 of 7
http://www.biomedcentral.com/1471-2407/14/590established. For example, Tublin et al. suggested that
the presence of intrathrombus enhancement is highly
indicative of neoplastic PVT [26]. However, CE-CT has
several disadvantages, including radiation exposure and
the use of contrast materials, which can lead to a fatal
induction of anaphylaxis and nephropathy [27-29].
This study has several limitations. The main limitation
is related to the method we used to generate the ROI for
evaluation. In our study, we drew ROIs manually and
calculated the phase values over the entire HCC and
thrombus, which might introduce unavoidable measure-
ment error. Secondly, due to the cross-sectional group
data we could not observe the dynamic SWI in different
courses of bland and neoplastic thrombi. Thirdly, because
abdomen SWI is sensitive to motion artifacts from
respiratory movement, our use of three consecutive
breath-hold acquisitions may not be feasible in all
cirrhotic patients, especially those with pulmonary com-
promise from hepatopulmonary syndrome or ascites.
Finally, it should be noted, SI of SWI is influenced
greatly by sequence parameters, especially echo time.
Our results only proved the SI value under current pa-
rameters. However, phase shift value is a real, explicable
index and will not change with sequence parameters. It
is certainly much more reliable.Conclusions
Neoplastic and bland PVT are both common in patients
with hepatocellular carcinoma. Our results suggest that
SW imaging is a promising new method for distinguishing
neoplastic from bland macroscopic thrombi. The high
sensitivity and specificity suggest its high value in clinical
practice.
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